tirzepatide vision loss risks in patients using popular GLP-1 medications raise concerns Tirzepatide Treatment | Blue Skies

Creates more continuous release pattern

Common side effects include gastrointestinal issues like nausea and diarrhea

Tirzepatide works by activating GIP and GLP-1 receptors, two natural pathways involved in appetite regulation and metabolism

Here is a side-by-side comparison based on available trial data: Semaglutide 2.4 mg (Wegovy): 14.9% average weight loss over 68 weeks, GLP-1 receptor agonist only Tirzepatide 15 mg (Zepbound/Mounjaro): 20.9% average weight loss over 72 weeks, dual GLP-1 and GIP agonist Retatrutide 12 mg: 24.2% average weight loss over 48 weeks, triple GLP-1, GIP, and glucagon agonist What I found interesting in the data is that retatrutide appears to produce faster early weight loss than either semaglutide or tirzepatide

Whether it is our Liposomal Glutathione or our NMN + Trans-Resveratrol for cellular energy, we focus on clean, science-forward formulations